Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$1.70 USD
-0.01 (-0.59%)
Updated Aug 28, 2024 01:36 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Company Summary
Plymouth, MI-based Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for CV diseases caused by elevated levels of LDL-C ("bad cholesterol").
Esperion has two approved drugs — Nexletol (bempedoic acid [180mg] and Nexlizet (bempedoic acid [180mg]/ ezetimibe [10mg] combination pill) — in its portfolio. The drugs are approved as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C in the ...
Company Summary
Plymouth, MI-based Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for CV diseases caused by elevated levels of LDL-C ("bad cholesterol").
Esperion has two approved drugs — Nexletol (bempedoic acid [180mg] and Nexlizet (bempedoic acid [180mg]/ ezetimibe [10mg] combination pill) — in its portfolio. The drugs are approved as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C in the United States. The drugs were approved in 2020.
In Europe, Nexletol is available as Nilemdo and Nexlizet is marketed as Nustendi.
Esperion has an agreement with Daiichi Sankyo Europe for commercialization rights to Nilemdo and Nustendi in Europe. The companies are expanding their agreement to include additional countries.
Esperion signed a collaboration agreement with Japan-based Otsuka Pharmaceutical for the development and commercialization of Nexletol and Nexlizet tablets in Japan in April 2020. These deals generate revenues through milestone payments and tiered royalties on net sales of the drugs.
Esperion recorded $116.3 million in total revenues in 2023, increasing 54% year over year.
General Information
Esperion Therapeutics, Inc
3891 RANCHERO DRIVE SUITE 150
ANN ARBOR, MI 48108
Phone: 734-887-3903
Fax: NA
Email: investorrelations@esperion.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.16 |
Current Year EPS Consensus Estimate | -0.04 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 1.71 |
52 Week High | 3.40 |
52 Week Low | 0.70 |
Beta | 1.02 |
20 Day Moving Average | 4,639,507.00 |
Target Price Consensus | 8.08 |
4 Week | -26.29 |
12 Week | -24.00 |
YTD | -42.81 |
4 Week | -28.77 |
12 Week | -28.52 |
YTD | -51.51 |
Shares Outstanding (millions) | 196.23 |
Market Capitalization (millions) | 335.54 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 89.13% |
vs. Previous Quarter | -114.71% |
vs. Previous Year | 186.33% |
vs. Previous Quarter | -46.39% |
Price/Book | NA |
Price/Cash Flow | NA |
Price / Sales | 1.21 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | -15.71 |
3/31/24 | -33.44 |
12/31/23 | -91.62 |
6/30/24 | 1.97 |
3/31/24 | 2.22 |
12/31/23 | 1.29 |
6/30/24 | 1.49 |
3/31/24 | 1.78 |
12/31/23 | 0.87 |
6/30/24 | -16.29 |
3/31/24 | -37.65 |
12/31/23 | -179.87 |
6/30/24 | -35.46 |
3/31/24 | -37.65 |
12/31/23 | -179.87 |
6/30/24 | -35.46 |
3/31/24 | -37.65 |
12/31/23 | -179.87 |
6/30/24 | -1.75 |
3/31/24 | -1.55 |
12/31/23 | -3.85 |
6/30/24 | 0.74 |
3/31/24 | 0.71 |
12/31/23 | 0.86 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |